Nirmatrelvir with Ritonavir is an oral antiviral combination developed for the treatment of COVID-19, especially in high-risk individuals.
This combination was created to block viral replication early in the infection and prevent progression to severe disease.

The therapy received its first major regulatory authorisation under Emergency Use Authorisation (EUA) by the U.S. FDA in December 2021.
Following this, it was approved or granted emergency authorisation by regulatory agencies worldwide, including:

• European Medicines Agency (EMA) – 2022
  

• UK MHRA – December 2021
  

• India (DCGI) – early 2022

Since then, Nirmatrelvir + Ritonavir has become a key outpatient treatment for individuals at higher risk of developing severe COVID-19, reducing hospitalisation and mortality when given early.

Nirmatrelvir (Nirmatrelvir + Ritonavir) is used to:

• Treat mild to moderate COVID-19 in adults at high risk of complications
  

• Prevent progression to severe illness, hospitalisation, or death.
  

• Reduce viral load and shorten symptom duration.
  

• Provide early antiviral control in immunocompromised or vulnerable patients.
  

It must be started within 5 days of symptom onset for best results.

Nirmatrelvir works through a dual-component antiviral mechanism:

1. Nirmatrelvir – Main Antiviral Agent

• Nirmatrelvir inhibits the SARS-CoV-2 3CL protease, an enzyme essential for viral replication.
  

• Blocking this enzyme prevents the virus from maturing and multiplying inside the body.
  

2. Ritonavir – Pharmacokinetic Booster

• Ritonavir does not act directly against COVID-19.
  

• It slows down the breakdown of Nirmatrelvir by inhibiting CYP3A4 enzymes in the liver.
  

• This increases Nirmatrelvir’s concentration and ensures effective antiviral levels throughout treatment.

• Nirmatrelvir is taken orally, usually as two components together:
  

  • Nirmatrelvir tablets
    

  • Ritonavir tablets
    

• It is taken twice daily for 5 days.
  

Typical regimen for adults:

• 300 mg Nirmatrelvir + 100 mg Ritonavir every 12 hours for 5 days
  (The exact composition depends on the manufacturer’s tablet strength.)

Nirmatrelvir side effects are 

Serious Side Effects:

• Severe allergic reaction (swelling, breathing difficulty)
  

• Hepatitis or liver enzyme elevation
  

• Significant drug interaction effects
  

• Irregular heartbeat
  

• Severe abdominal pain
  

Common Side Effects:

• Altered taste (metallic taste)
  

• Diarrhea
  

• High blood pressure
  

• Muscle aches
  

• Nausea or vomiting
  

• Headache

Contact your doctor if symptoms worsen or do not improve.

• Not recommended for use with certain CYP3A4-dependent medications, as dangerous interactions may occur.
  

• Contraindicated in patients with:
  

  • Severe kidney disease
    

  • Severe liver impairment
    

  • Known hypersensitivity to either component
    

• May cause altered taste, diarrhoea, changes in blood pressure, or drug-interaction-related effects.
  

• Patients with heart rhythm disorders should use it with caution due to the potential for ECG changes.
  

• Ritonavir can interact with multiple medications, including:
  

  • Antiarrhythmics
    

  • Antiseizure drugs
    

  • Immunosuppressants
    

  • Sedatives
    

  • Antipsychotics
    

  • Blood thinners
    

• Avoid use during pregnancy unless the benefits outweigh the risks.

• Inform your doctor about all your medications, including:
  

  • Blood pressure medicines
    

  • Antidepressants
    

  • Steroids
    

  • Diabetes medicines
    

  • Herbal supplements (especially St. John’s Wort)
    

• Patients should have their kidney and liver function reviewed before prescribing.
  

• Do not stop or adjust other chronic medications without medical advice.
  

• Continue monitoring of symptoms during and after therapy.
  

• Not a substitute for vaccination; must be used only for active infection.
  

• Store in a cool, dry place away from light and moisture.

• Start Nirmatrelvir within 5 days of symptoms for best results.
  

• Do not stop or skip doses, even if symptoms improve early.
  

• Inform your doctor about ALL current medications.
  

• Stay hydrated, rest well, and monitor oxygen levels if advised.
  

• This medicine is not for preventive use and is not a replacement for vaccination.
  

• Continue isolation and safety measures as recommended.

1. Hammond J. et al. (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. New England Journal of Medicine https://www.nejm.org/doi/full/10.1056/NEJMoa2118542?
   

2. Pfizer. Paxlovid (Nirmatrelvir + Ritonavir) Emergency Use Authorization Fact Sheet https://www.fda.gov/media/155050/download?
   

3. World Health Organization (WHO) COVID-19 Treatment Guidelines https://www.who.int/therapeutics?

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.